Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EPS (Weighted Average and Diluted) (2023 - 2025)

Iovance Biotherapeutics has reported EPS (Weighted Average and Diluted) over the past 3 years, most recently at -$201.34 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$201.34 for Q4 2025, down 80437.3% from a year ago — trailing twelve months through Dec 2025 was -$201.34 (down 15508.0% YoY), and the annual figure for FY2025 was -$1.09, up 14.84%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$201.34 at Iovance Biotherapeutics, down from -$0.33 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for IOVA hit a ceiling of -$0.25 in Q4 2024 and a floor of -$201.34 in Q4 2025.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$0.42 (2024), compared with a mean of -$18.65.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 44.44% in 2024 and later plummeted 80437.3% in 2025.
  • Iovance Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$0.45 in 2023, then skyrocketed by 44.44% to -$0.25 in 2024, then plummeted by 80437.3% to -$201.34 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$201.34 (Q4 2025), -$0.33 (Q2 2025), and -$0.36 (Q1 2025) per Business Quant data.